Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
HLS Therapeutics Inc
HLSHLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada. Address: 10 Carlson Court, Etobicoke, ON, Canada, M9W 6L2
Analytics
Zielpreis von Wall Street
7.51 CADKGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen HLS
Dividenden-Analyse HLS
Dividendenwachstum über 5 Jahre
100 %Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
-31 %Verlauf der Dividende HLS
Bewertung der Aktie HLS
Finanzen HLS
Ergebnisse | 2019 | Dynamik |